Myfortic or CellCept Gastrointestinal Effects in African American Kidney Recipients
Status:
Terminated
Trial end date:
2011-01-01
Target enrollment:
Participant gender:
Summary
Myfortic (enteric-coated mycophenolate sodium) has been shown to have similar effectiveness
to CellCept (mycophenolate mofetil) in preventing rejection in kidney transplant recipients.
However, enteric coated mycophenolate sodium has been thought to possibly be associated with
fewer gastrointestinal side effects. Mycophenolate mofetil and enteric coated mycophenolate
sodium pharmacokinetics (how the drug is absorbed and broken down) have not been well-studied
in African American kidney transplant recipients. The investigators are interested in
studying enteric coated mycophenolate sodium and mycophenolate mofetil pharmacokinetics and
gastrointestinal side effects in African American kidney transplant recipients.